Cortechs.ai | Automated volumetry for prediction of MMSE and CDR decline

Automated volumetry for prediction of MMSE and CDR decline

High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment

This study examined whether measures of hippocampus, amygdala, and temporal horn volume predict clinical decline over the following 6-month period in patients with mild cognitive impairment (MCI). Fully automated volume measurements were performed in 269 MCI patients. Baseline volumes of the hippocampus, amygdala, and temporal horn were evaluated as predictors of change in Mini-mental State Examination and Clinical Dementia Rating Sum of Boxes over a 6-month interval. Fully automated measurements of baseline hippocampus and amygdala volumes correlated with baseline delayed recall scores. (2009).

[button]Download[/button]

More Resources

11/04/2025

NeuroQuant Dementia in Different Use Cases 

NeuroQuant transforms brain imaging into a measurable biomarker for neurodegeneration by combining volumetric data with clinical expertise.

10/29/2025

Enhancing Brain Tumor Treatment with RT STRUCT Images: The Promise of Automation

Automating the generation of RT STRUCT images with NeuroQuant Brain Tumor can streamline workflows and elevate the standard of care

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.
Scroll to Top